



ALLERGIC REACTION / ANAPHYLAXIS

Effective: January 1, 2025
Replaces: April 27, 2017

1. Patient Care Goals

- 1.1. Maintain a patent airway
- 1.2. Recognize impending respiratory failure
- 1.3. Promptly identify and intervene for patients who require escalation of therapy
- 1.4. Provide timely therapy for potentially life-threatening reactions to known or suspected allergens to prevent cardiorespiratory collapse and shock
- 1.5. Provide symptomatic relief for symptoms due to known or suspected allergens

2. BLS Treatment

- 2.1. Routine Medical Care – Adult (700-S04)
 - 2.1.1. **Oxygen** – titrate as appropriate
- 2.2. Treat for signs and symptom of shock as necessary (700-A10)
- 2.3. Place patient in a position that decreases work of breathing

3. ALS Treatment

- 3.1. **Vascular Access (IV) or Vascular Access (IO)**, per procedure (700-M13)

4. Allergic Reaction (Rash, itching or swelling)

- 4.1. **Diphenhydramine 50mg IV / IO / IM**
- 4.2. For wheezing and mild respiratory distress administer **Albuterol 5mg in 6ml normal saline** via nebulizer device or BVM

5. Anaphylaxis (Respiratory distress, difficulty swallowing, tightness to chest or throat)

- 5.1. **Epinephrine (1:1,000) 0.3mg IM**, may repeat every 10 minutes, max dose 0.9mg
- 5.2. For persistent wheezing and mild respiratory distress administer **Albuterol 5mg in 6ml normal saline** via nebulizer device or BVM
- 5.3. **Diphenhydramine 50mg IV / IO / IM**, for hives and/or itching

6. Anaphylactic Shock

- 6.1. If signs of shock are present:
 - 6.1.1. **Epinephrine (1:1,000) 0.3mg IM**, may repeat every 10 minutes, max dose 0.9mg
 - 6.1.2. **250ml Fluid bolus IV / IO**, may repeat 4 times for a total of 1,000ml
- 6.2. If vital signs do not improve after 10 minutes post epinephrine and fluid bolus:
 - 6.2.1. **BASE CONTACT: Epinephrine 0.1mg (1:10,000) Slow IV / IO**
 - 6.2.1.1. Dilute **1mL of Epinephrine (1:10,000) in 9mL of Normal Saline** and administer slowly over 3-5 minutes

7. Pertinent Assessment Findings


- 7.1. Presence or absence of angioedema
- 7.2. Presence or absence of respiratory compromise
- 7.3. Presence or absence of circulatory compromise
- 7.4. Localized or generalized urticaria
- 7.5. Response to therapy



8. Key Documentation Elements

- 8.1. Medications given
- 8.2. Dose and concentration of epinephrine given
- 8.3. Route of epinephrine administration
- 8.4. Time of epinephrine administration
- 8.5. Signs and symptoms of the patient

9. Allergic Reaction / Anaphylaxis Treatment Flow Chart



Protocol # 700-A12